Sara M. Tolaney, MD, MPH

Articles

Patient Profile 2: Strategies for Managing Brain Metastases in HER2+ Metastatic Breast Cancer

May 26th 2022

Shared insight on strategies for managing brain metastases in patients with HER2+ breast cancer.

Patient Profile 2: 26-Year-Old Woman With Triple Positive Breast Cancer

May 26th 2022

Shanu Modi, MD, presents the clinical scenario of a 26-year-old woman with triple positive breast cancer.

Patient Profile 1: Trastuzumab Deruxtecan for HER2+ Metastatic BC

May 19th 2022

Expert perspectives on the use of trastuzumab deruxtecan in a patient with HER2+ metastatic breast cancer.

Patient Profile 1: 62-Year-Old Woman With Metastatic Breast Cancer

May 19th 2022

Breast medical oncologist, Tiffany Traina, MD, shares a clinical scenario of a patient with HER2+ metastatic breast cancer and discusses her treatment approach in the neoadjuvant, adjuvant, and metastatic settings.

Dr. Tolaney on Pivotal Trials in HER2+ Breast Cancer

March 9th 2022

Sara M. Tolaney, MD, MPH, discusses pivotal trials in HER2-positive breast cancer.

Dr. Tolaney on Potential of Trastuzumab Deruxtecan to Shift to First Line in HER2+ Breast Cancer

March 4th 2022

Sara M. Tolaney, MD, MPH, discusses the efficacy of trastuzumab deruxtecan in the second-line setting and its potential to move into the first-line treatment of HER2-positive breast cancer.

Dr. Tolaney on the Efficacy of Zanidatamab Plus Chemo in HER2+ Breast Cancer

January 14th 2022

Sara M. Tolaney, MD, MPH, sheds light on zanidatamab and the data reported with the agent in combination with chemotherapy for the treatment of patients with HER2-positive breast cancer.

Dr. Tolaney on the Importance of Evaluating Enobosarm in ER+ Breast Cancer

January 5th 2022

Sara M. Tolaney, MD, MPH, chief, discusses the importance of evaluating enobosarm in metastatic estrogen receptor–positive, HER2-negative breast cancer.

ESMO 2021: Updates in Triple Negative Breast Cancer

November 15th 2021

Drs Joyce O’Shaughnessy, Sara Tolaney, Sara Hurvitz, and Mark Pegram examine recent trial data from ESMO 2021 on triple-negative breast cancer.

Updates in HR+/HER2- Breast Cancer: The MONALEESA-2 Trial

November 8th 2021

Breast oncologists explain results from the phase III MONALEESA-2 trial presented at ESMO 2021, and its clinical implications.

Interesting Trials in HER2+ Breast Cancer

November 1st 2021

Key opinion leaders review data from the phase III TULIP trial in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer and the ExteNET study on extended adjuvant treatment with neratinib.

Future Landscape of HER2+ MBC

October 26th 2021

Drs. Sara Tolaney and Mark Pegram discuss promising therapies and upcoming mechanisms of actions to treat HER2+ metastatic breast cancer.

Other Trials with Trastuzumab Deruxtecan in Breast Cancer

October 26th 2021

Breast cancer experts, Drs. Sara Tolaney and Mark Pegram discuss ongoing and noteworthy trials with trastuzumab deruxtecan in mBC.

Sequencing in HER2+ MBC

October 26th 2021

Sara Tolaney, MD, and Mark Pegram, MD, discuss their rationale for sequencing of most effective therapy in treatment of patients with metastatic breast cancer.

Updates in HER2+ Breast Cancer from ESMO 2021

October 25th 2021

Expert oncologists discuss data from several phase 2 and phase 3 trials presented at ESMO 2021 on the use of trastuzumab deruxtecan for HER2-positive breast cancer and how it impacts their practices.

Experience with Trastuzumab Deruxtecan in Breast Cancer

October 21st 2021

Breast cancer experts, Sara Tolaney, MD, and Mark Pegram, MD, discuss current standard of care in sequencing of therapies in mBC and the effect of DESTINY-Breast03 data on sequencing going forward.

DESTINY-Breast03 Trial in HER2+ mBC

October 21st 2021

Mark Pegram, MD, and Sara Tolaney, MD, review the DESTINY-Breast03 study design, clinical efficacy, and safety data.

Trastuzumab Derxutecan in HER2+ mBC

October 21st 2021

Sara Tolaney, MD, describes trastuzumab deruxtecan and the data that led to its accelerated approval in HER2+ breast cancer.

Historical Perspective of HER2+ Breast Cancer

October 21st 2021

Mark Pegram, MD, provides a historical perspective on recent advancements made in the treatment landscape for patients with HER2-positive breast cancer.

Dr. Tolaney on Key Findings From the ExteNET Trial in HER2+ Breast Cancer

July 29th 2021

Sara M. Tolaney, MD, MPH, discusses data from the phase 3 ExteNET trial utilizing neratinib in the treatment of patients with HER2-positive breast cancer.